Identification of recent exacerbations in COPD patients by electronic nose.

Molecular profiling of exhaled breath by electronic nose (eNose) might be suitable as a noninvasive tool that can help in monitoring of clinically unstable COPD patients. However, supporting data are still lacking. Therefore, as a first step, this study aimed to determine the accuracy of exhaled breath analysis by eNose to identify COPD patients who recently exacerbated, defined as an exacerbation in the previous 3 months. Data for this exploratory, cross-sectional study were extracted from the multicentre BreathCloud cohort. Patients with a physician-reported diagnosis of COPD (n=364) on maintenance treatment were included in the analysis. Exacerbations were defined as a worsening of respiratory symptoms requiring treatment with oral corticosteroids, antibiotics or both. Data analysis involved eNose signal processing, ambient air correction and statistics based on principal component (PC) analysis followed by linear discriminant analysis (LDA). Before analysis, patients were randomly divided into a training (n=254) and validation (n=110) set. In the training set, LDA based on PCs 1-4 discriminated between patients with a recent exacerbation or no exacerbation with high accuracy (receiver operating characteristic (ROC)-area under the curve (AUC)=0.98, 95% CI 0.97-1.00). This high accuracy was confirmed in the validation set (AUC=0.98, 95% CI 0.94-1.00). Smoking, health status score, use of inhaled corticosteroids or vital capacity did not influence these results. Exhaled breath analysis by eNose can discriminate with high accuracy between COPD patients who experienced an exacerbation within 3 months prior to measurement and those who did not. This suggests that COPD patients who recently exacerbated have their own exhaled molecular fingerprint that could be valuable for monitoring purposes.

Informations de copyright

Copyright ©ERS 2020.

Déclaration de conflit d'intérêts

Conflict of interest: J.J.M.H. van Bragt reports an unrestricted research grant from Boehringer Ingelheim during the conduct of the study. Conflict of interest: P. Brinkman has nothing to disclose. Conflict of interest: R. de Vries is COO of and has a considerable interest in the start-up company Breathomix BV. Conflict of interest: S.J.H. Vijverberg has nothing to disclose. Conflict of interest: E.J.M. Weersink has nothing to disclose. Conflict of interest: E.G. Haarman has nothing to disclose. Conflict of interest: F.H.C. de Jongh has nothing to disclose. Conflict of interest: S. Kester has nothing to disclose. Conflict of interest: A. Lucas has nothing to disclose. Conflict of interest: J.C.C.M. in 't Veen reports faculty grants from Boehringer Ingelheim, Teva and Chiesi, and personal fees for an international advisory board from Sanofi, outside the submitted work. Conflict of interest: P.J. Sterk reports being scientific advisor to and having a formally inconsiderable interest in the start-up company Breathomix BV. Conflict of interest: E.H.D. Bel reports grants and personal fees from AstraZeneca, GSK, Novartis, and Teva, and personal fees from Sanofi/Regeneron, Boehringer Ingelheim, Vectura, and Sterna, outside the submitted work. Conflict of interest: A.H. Maitland-van der Zee reports personal fees for advisory boards from AstraZeneca and Boehringer Ingelheim, and unrestricted research grants from Boehringer Ingelheim and GSK, during the conduct of the study.